SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Edqvist Per Henrik D)
 

Search: WFRF:(Edqvist Per Henrik D) > (2015-2019) > Consequences of a h...

  • Aasebö, Kristine Ö.Univ Bergen, Dept Clin Sci, Bergen, Norway (author)

Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors : A population-based cohort of metastatic colorectal cancer patients

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • 2019-05-09
  • WILEY,2019
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-391954
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-391954URI
  • https://doi.org/10.1002/cam4.2205DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Immunotherapy for patients with microsatellite-instable (MSI-H) tumors or BRAF-inhibitors combination treatment for BRAF-mutated (mutBRAF) tumors in metastatic colorectal cancer (mCRC) is promising, but the frequency of these molecular changes in trial patients are low. Unselected population-based studies of these molecular changes are warranted.Methods: A population-based cohort of 798 mCRC patients in Scandinavia was studied. Patient and molecular tumor characteristics, overall survival (OS) and progression-free survival (PFS) were estimated.Results: Here, 40/583 (7%) tumor samples were MSI-H and 120/591 (20%) were mutBRAF; 87% of MSI-H tumors were mutBRAF (non-Lynch). Elderly (>75 years) had more often MSI-H (10% vs 6%) and MSI-H/mutBRAF (9% vs 4%) tumors. Response rate (5% vs 44%), PFS (4 vs 8 months), and OS (9 vs 18 months) after first-line chemotherapy was all significantly lower in patients with MSI-H compared to patients with microsatellite stable tumors. MSI-H and mutBRAF were both independent poor prognostic predictors for OS (P = 0.049, P < 0.001) and PFS (P = 0.045, P = 0.005) after first-line chemotherapy. Patients with MSI-H tumors received less second-line chemotherapy (15% vs 37%, P = 0.005).Conclusions: In unselected mCRC patients, MSI-H and mutBRAF cases were more common than previously reported. Patients with MSI-H tumors had worse survival, less benefit from chemotherapy, and they differed considerably from recent third-line immunotherapy trial patients as they were older and most had mutBRAF tumor (non-Lynch).

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Dragomir, AncaUppsala universitet,Klinisk och experimentell patologi,Fredrik Pontén(Swepub:uu)ancadrag (author)
  • Sundström, MagnusUppsala universitet,Klinisk och experimentell patologi(Swepub:uu)magnsund (author)
  • Mezheyeuski, ArturUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)artme913 (author)
  • Edqvist, Per-Henrik DUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)peedq227 (author)
  • Eide, Geir EgilUniv Bergen, Dept Global Publ Hlth & Primary Care, Lifestyle Epidemiol Grp, Bergen, Norway;Haukeland Hosp, Ctr Clin Res, Bergen, Norway (author)
  • Pontén, FredrikUppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk och experimentell patologi(Swepub:uu)fredpont (author)
  • Pfeiffer, PerOdense Univ Hosp, Dept Oncol, Odense, Denmark (author)
  • Glimelius, BengtUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)bengglim (author)
  • Sorbye, HalfdanUniv Bergen, Dept Clin Sci, Bergen, Norway;Haukeland Hosp, Dept Oncol, Bergen, Norway (author)
  • Univ Bergen, Dept Clin Sci, Bergen, NorwayKlinisk och experimentell patologi (creator_code:org_t)

Related titles

  • In:Cancer Medicine: WILEY8:7, s. 3623-36352045-7634

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view